Efficacy of low-dose erlotinib as maintenance therapy in patients of lung adenocarcinoma with EGFR mutatio
Not Applicable
- Conditions
- lung adenocarcinoma
- Registration Number
- JPRN-UMIN000005468
- Lead Sponsor
- ational center for global health and medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patient with severe complication (2) Patient with symptomatic brain metastasis (3) Patient with double cancer (4) Pregnant, breast feeding patient. Patient with possibility of pregnant (5) Patient with diarrhea (6) History of myocardial infarction within 3 months (7) Unsuitable patient for this study in opinion of doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate (CR+PR)
- Secondary Outcome Measures
Name Time Method Overall survival, progression-free survival, Disease control rate, frequency of adverse events, QO
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie low-dose erlotinib's efficacy in EGFR-mutated lung adenocarcinoma maintenance therapy?
How does low-dose erlotinib compare to standard EGFR inhibitors like osimertinib in long-term survival outcomes for EGFR-mutated lung adenocarcinoma?
Which biomarkers correlate with response to low-dose erlotinib maintenance therapy in EGFR-mutated non-small cell lung cancer (NSCLC)?
What are the safety profiles and management strategies for adverse events in low-dose erlotinib maintenance therapy for EGFR-mutated lung adenocarcinoma?
What combination therapies with low-dose erlotinib are being explored for EGFR-mutated lung adenocarcinoma beyond JPRN-UMIN000005468?